NASDAQ
86.38USD
-1.26 (-1.44%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.2B
P/E
—
EPS
—
Beta
0.16
52W range
38.93-151.02
Day range
85.46–88.50
Open
88.00
Prev close
87.64
Volume
677.9K
Avg volume
1.6M
Dividend
0.00
IPO
2017-09-19
https://www.businesswire.com/news/home/20260802229252/en/CELC-Investors-Have-Opportunity-to-Join-Celcuity-Inc.-Fraud-Investigation-with-SBS-Law/ · 8/2/2026-1.00
https://www.globenewswire.com/news-release/2026/07/28/3334849/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Celcuity-Inc-CELC.html · 7/28/2026-0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-hca-healthcare-inc---hca-302828037.html · 7/16/2026-0.80
https://www.marketbeat.com/instant-alerts/celcuity-enters-commercial-stage-as-fda-approves-revtorpyk-for-advanced-breast-cancer-2026-07-15/ · 7/15/2026+1.00
https://seekingalpha.com/article/4913744-celcuity-inc-celc-presents-at-goldman-sachs-47th-annual-global-healthcare-conference-2026 · 6/10/2026+0.80
https://www.globenewswire.com/news-release/2026/06/04/3306482/0/en/Celcuity-Inc-Announces-Pricing-of-Upsized-Public-Offering-of-0-250-Convertible-Senior-Notes-Due-2032.html · 6/4/2026+0.40
https://www.globenewswire.com/news-release/2026/05/14/3295313/0/en/Celcuity-Inc-Reports-Release-of-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html · 5/14/2026+0.60
https://www.globenewswire.com/news-release/2026/03/25/3262558/0/en/Celcuity-Inc-Reports-Release-of-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html · 3/25/2026+0.40
https://seekingalpha.com/article/4880682-celcuity-inc-celc-presents-at-leerink-global-healthcare-conference-2026-transcript · 3/10/2026+0.10
https://www.fool.com/coverage/filings/2026/02/22/celcuity-stock-soars-700-in-a-year-as-one-investor-s-usd17-million-buy-helps-create-top-two-position/ · 2/22/2026+1.00
https://www.zacks.com/commentary/2803323/tracking-the-top-performing-russell-2000-stocks-against-the-zacks-rank?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2803323 · 12/12/2025+0.80
https://www.globenewswire.com/news-release/2025/12/11/3204248/0/en/Celcuity-Presents-Updated-Results-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html · 12/11/2025+1.00
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
